Pfizer's management has reaffirmed its commitment to maintaining and growing the dividend, even as the stock's yield has surged to 6.8% amid industry headwinds. In the first-quarter 2026 earnings presentation, two slides explicitly prioritized the dividend, with one stating the goal to 'maintain and grow our dividend' and another listing 'maintain dividend' as a long-term objective. The company paid $2.445 billion in dividends during the first quarter, an annualized rate of nearly $10 billion, while generating $2.6 billion from operating activities. After dividends, debt payments, and business investments, Pfizer's cash balance still rose by $560 million, aided by sales of long-term investments, and it held $11.3 billion in long-term investments plus $1.7 billion in cash at quarter-end. The high yield reflects investor concerns over upcoming patent expirations and a lag in new drug development, including a setback in the GLP-1 weight-loss space, but management's public support and the company's liquidity suggest the dividend is not in immediate danger.
Pfizer IncManagement reaffirmed commitment to maintain and grow dividend, supported by strong cash flow and liquidity.